Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "infectious-diseases"

182 News Found

Moderna announces expansion in key Asian markets
News | February 16, 2022

Moderna announces expansion in key Asian markets

New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong


TATA MD’s OmiSure detects all Omicron variants
Medical Device | February 09, 2022

TATA MD’s OmiSure detects all Omicron variants

According to ICMR, the upgraded OmiSure RT-PCR test for Covid-19 successfully detects all sub-types of Omicron that are currently prevalent in India


Sputnik V vaccine granted full approval in Russia
News | February 04, 2022

Sputnik V vaccine granted full approval in Russia

Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world


Merck donates 1.5 billionth tablet of praziquantel to Africa
Public Health | January 25, 2022

Merck donates 1.5 billionth tablet of praziquantel to Africa

The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007


Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study
News | January 21, 2022

Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study

An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv


Molnupiravir best option to treat Covid-19 now: Experts
News | January 11, 2022

Molnupiravir best option to treat Covid-19 now: Experts

Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients


Pfizer and BioNTech to develop first mRNA-based Shingles vaccine
Biotech | January 07, 2022

Pfizer and BioNTech to develop first mRNA-based Shingles vaccine

Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022


China approves Brii Bio’s antibody combination to neutralise Covid-19
Drug Approval | December 10, 2021

China approves Brii Bio’s antibody combination to neutralise Covid-19

Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA


Hilleman Laboratories invests US $ 58 mn to establish vaccine hub in Singapore
Biotech | December 07, 2021

Hilleman Laboratories invests US $ 58 mn to establish vaccine hub in Singapore

The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.


Roche completes acquisition of TIB Molbiol
Medical Device | December 01, 2021

Roche completes acquisition of TIB Molbiol

TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic